The tens of billions of oral hypoglycemic drugs market has new competitors entering the market

Diabetes is a chronic metabolic disease that is caused by genetic factors, environmental factors and living habits, and seriously threatens human health
.
Due to the change of life>
.
Currently, medications for this disease mainly include oral hypoglycemic drugs, insulin and their analogs
.
For most patients, oral hypoglycemic drugs are a more economical, practical and convenient treatment option
.
Therefore, oral hypoglycemic drugs account for most of the market share of diabetes drugs
.
Domestically, in 2020, the sales of oral hypoglycemic drugs in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have reached nearly 25 billion yuan
.
It is understood that there are currently 7 major categories of oral hypoglycemic drugs, including biguanides, sulfonylureas, thiazolidinediones, glinides, α-glycosidase inhibitors, dipeptidyl peptidase IV (DPP-4 ) Inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors
.
With the continuous expansion of the oral hypoglycemic drug market, many pharmaceutical companies have also begun to rush to lay out the popular drugs among them
.
Recently, Buchang Pharmaceutical issued an announcement stating that the clinical application of the wholly-owned subsidiary Shandong Danhong's Class 1 new drugs BC0305 Capsules and BC0306 Capsules has been accepted by CDE
.
According to data, BC0305 is a medicine intended to improve the blood sugar control of patients with type 2 diabetes on the basis of diet and exercise
.
BC0306 is mainly used for the treatment of non-alcoholic steatohepatitis.
There is currently no drug on the market with the same target at home and abroad
.
According to the announcement, as of December 21, 2021, Buchang Pharmaceuticals invested approximately RMB 26,550,300 in R&D expenses on the BC0305 project, and approximately RMB 27,998,400 in R&D expenses on the BC0306 project
.
With the huge market prospects and there are still many unmet clinical needs for diabetes treatment, more and more domestic pharmaceutical companies are actively deploying
.
In addition to Buchang Pharmaceuticals, Chengdu Better Pharmaceuticals also submitted an application for the imitation of Enpagliflozin Tablets for the 4th category, which was undertaken by CDE
.
In fact, in recent years, Chengdu Better Pharmaceuticals has been accelerating its R&D layout in the field of diabetes medications.
On June 21 this year, the website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical’s Metformin Hydrochloride Sustained-Release Tablets are imitations of 4 types.
The application for production is approved, and it is deemed as over-evaluated
.
In addition, it also has two marketing applications for oral hypoglycemic drugs under review and approval
.
In addition, on January 21, the State Food and Drug Administration public information showed that Hunan Qianjin Xiangjiang Pharmaceutical's acarbose tablets were approved for production in four types of imitations, and they were deemed to have been reviewed
.
Data show that acarbose tablets are suitable for the treatment of type 2 diabetes, and also suitable for reducing the postprandial blood sugar of people with impaired glucose tolerance
.
Data shows that the sales of Acarbose tablets in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 8 billion yuan
.
Generally speaking, in recent years, domestic pharmaceutical companies are constantly changing the monopoly of the diabetes market by large pharmaceutical companies through R&D and innovation
.
In the future, as more and more high-tech and high-barrier drugs are approved for listing by domestic companies, it will become a general trend that domestic drugs replace original research
.